These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 22086231)
1. An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Spies E; Reichardt W; Alvarez G; Groettrup M; Ohlschläger P Mol Ther; 2012 Mar; 20(3):555-64. PubMed ID: 22086231 [TBL] [Abstract][Full Text] [Related]
2. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977 [TBL] [Abstract][Full Text] [Related]
3. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683 [TBL] [Abstract][Full Text] [Related]
4. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model. Simons BW; Cannella F; Rowley DT; Viscidi RP Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503 [TBL] [Abstract][Full Text] [Related]
5. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Johnson LE; McNeel DG Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020 [TBL] [Abstract][Full Text] [Related]
6. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470 [TBL] [Abstract][Full Text] [Related]
7. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related]
9. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648 [TBL] [Abstract][Full Text] [Related]
11. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116 [TBL] [Abstract][Full Text] [Related]
12. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078 [TBL] [Abstract][Full Text] [Related]
13. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108 [TBL] [Abstract][Full Text] [Related]
16. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222 [TBL] [Abstract][Full Text] [Related]
17. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260 [TBL] [Abstract][Full Text] [Related]
18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
19. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682 [TBL] [Abstract][Full Text] [Related]
20. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. Grossmann ME; Davila T; Celis T J Immunother; 2001; 24(3):237-41. PubMed ID: 11394501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]